

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 30 MAY 2025

CSPC Pharmaceutical Group Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting (the “**AGM**”) of the Company held on 30 May 2025 as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited financial statements, the report of the directors and the independent auditor’s report for the year ended 31 December 2024.	6,948,640,835 (99.89%)	7,725,078 (0.11%)
2.	To declare a final dividend of HK10 cents per share for the year ended 31 December 2024.	6,956,359,913 (99.99%)	6,000 (0.01%)
3.	(a)(i) To re-elect Mr. WANG Zhenguo as an executive director.	6,779,803,918 (97.46%)	176,557,995 (2.54%)
	(a)(ii) To re-elect Mr. PAN Weidong as an executive director.	6,779,803,918 (97.46%)	176,557,995 (2.54%)
	(a)(iii) To re-elect Mr. WANG Huaiyu as an executive director.	6,779,803,918 (97.46%)	176,557,995 (2.54%)
	(a)(iv) To re-elect Dr. YAO Bing as an executive director.	6,764,174,713 (97.24%)	192,187,200 (2.76%)

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
	(a)(v) To re-elect Mr. CAI Xin as an executive director.	6,781,913,918 (97.49%)	174,447,995 (2.51%)
	(a)(vi) To re-elect Mr. CHEN Weiping as an executive director.	6,783,987,750 (97.52%)	172,374,163 (2.48%)
	(a)(vii) To re-elect Mr. WANG Bo as an independent non-executive director.	5,495,877,660 (79.01%)	1,460,484,253 (20.99%)
	(a)(viii) To re-elect Mr. CHEN Chuan as an independent non-executive director.	6,715,387,089 (96.54%)	240,974,824 (3.46%)
	(b) To authorize the board of directors to fix the remuneration of directors.	6,938,299,664 (99.74%)	18,066,249 (0.26%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditor and to authorise the board of directors to fix the remuneration of auditor.	6,882,844,901 (98.94%)	73,521,012 (1.06%)
5.	To give a general mandate to the Directors to buy-back shares of the Company (ordinary resolution in item No.5 of the Notice of Annual General Meeting).	6,952,946,155 (99.95%)	3,419,758 (0.05%)
6.	To give a general mandate to the Directors to issue new shares of the Company (ordinary resolution in item No.6 of the Notice of Annual General Meeting).	6,808,489,738 (97.87%)	147,876,175 (2.13%)
7.	To grant a mandate to the Directors to grant options under the Share Option Scheme of the Company (ordinary resolution in item No.7 of the Notice of Annual General Meeting).	6,126,251,337 (88.07%)	830,114,576 (11.93%)

As more than 50% of the votes were cast in favour of ordinary resolutions 1 to 7, all such resolutions were duly passed as ordinary resolutions at the AGM.

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 11,518,251,732 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 11,518,251,732 shares. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and no holder of shares was required to abstain from voting at the AGM under the Listing Rules.

There were no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System (CCASS)) nor shares repurchased by the Company pending cancellation.

Tricor Investor Services Limited, the Share Registrar of the Company, acted as scrutineer for the poll at the AGM.

The AGM was chaired by Mr. CAI Dongchen, the Chairman of the Board. All directors of the Company (except for Mr. PAN Weidong, Mr. WANG Bo and Ms. LI Quan who were unable to attend due to other commitments) attended the AGM in person or by electronic means.

Shareholders may refer to the circular dated 29 April 2025 for details of the above resolutions proposed at the AGM. The circular may be viewed and downloaded from the Company's website at www.irasia.com/listco/hk/cspc or the designated website of The Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk.

By order of the board
CSPC Pharmaceutical Group Limited
LO Tai On
Company Secretary

Hong Kong, 30 May 2025

Following the conclusion of the 2025 AGM, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.